IL100549A - Antiherpes pharmaceutical and cosmetic compositions comprising a combination of an antiviral nucleoside analog and a ribonucleotide reductase inhibiting peptide derivative - Google Patents

Antiherpes pharmaceutical and cosmetic compositions comprising a combination of an antiviral nucleoside analog and a ribonucleotide reductase inhibiting peptide derivative

Info

Publication number
IL100549A
IL100549A IL10054991A IL10054991A IL100549A IL 100549 A IL100549 A IL 100549A IL 10054991 A IL10054991 A IL 10054991A IL 10054991 A IL10054991 A IL 10054991A IL 100549 A IL100549 A IL 100549A
Authority
IL
Israel
Prior art keywords
asp
tbg
val
cypn
pyrrolidino
Prior art date
Application number
IL10054991A
Other languages
English (en)
Other versions
IL100549A0 (en
Inventor
Robert Deziel
Yvan Guindon
Original Assignee
Bio Mega Boehringer Ingelheim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Mega Boehringer Ingelheim filed Critical Bio Mega Boehringer Ingelheim
Publication of IL100549A0 publication Critical patent/IL100549A0/xx
Publication of IL100549A publication Critical patent/IL100549A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Birds (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL10054991A 1990-12-31 1991-12-30 Antiherpes pharmaceutical and cosmetic compositions comprising a combination of an antiviral nucleoside analog and a ribonucleotide reductase inhibiting peptide derivative IL100549A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002033448A CA2033448C (fr) 1990-12-31 1990-12-31 Compositions contre l'herpes et mode d'utilisation

Publications (2)

Publication Number Publication Date
IL100549A0 IL100549A0 (en) 1992-09-06
IL100549A true IL100549A (en) 1995-11-27

Family

ID=4146737

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10054991A IL100549A (en) 1990-12-31 1991-12-30 Antiherpes pharmaceutical and cosmetic compositions comprising a combination of an antiviral nucleoside analog and a ribonucleotide reductase inhibiting peptide derivative

Country Status (9)

Country Link
US (1) US5552384A (fr)
EP (1) EP0493770B1 (fr)
JP (1) JP3209552B2 (fr)
AT (1) ATE156362T1 (fr)
AU (1) AU648855B2 (fr)
CA (1) CA2033448C (fr)
DE (1) DE69127184T2 (fr)
IL (1) IL100549A (fr)
NZ (1) NZ241121A (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846941A (en) * 1992-03-12 1998-12-08 Boehringer Ingelheim (Canada) Ltd. Isosteric antiherpes peptide derivatives II
EP0618226B1 (fr) * 1993-03-03 2000-11-29 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de ribonucléotide réductase de virus herpétique
CA2095408A1 (fr) * 1993-05-03 1994-11-04 James Gus Chafouleas Methode de lutte contre les infections par le virus de l'herpes simplex resistant a l'acyclovir
US5459063A (en) * 1993-10-14 1995-10-17 The University Of Pennsylvania Plasmodium falciparum ribonucleotide reductase DNA
JP2001508654A (ja) * 1996-12-27 2001-07-03 ベーリンガー インゲルハイム（カナダ）リミテッド ヒトのサイトメガロウイルスプロテアーゼ用の改良した基質
JP4110347B2 (ja) * 1999-11-05 2008-07-02 大鵬薬品工業株式会社 抗ｈｉｖ剤
WO2011035120A2 (fr) * 2009-09-17 2011-03-24 Gk Ventures, L.L.C. Composition thérapeutique pour traiter des lésions provoquées par le virus herpès simplex
US8853223B2 (en) 2010-09-17 2014-10-07 G2L Touch, Inc. Therapeutic composition to treat lesions caused by herpes simplex virus
JP2014141475A (ja) * 2012-12-27 2014-08-07 Daiichi Sankyo Co Ltd 新規美白剤
CA3112326A1 (fr) 2018-09-12 2020-03-19 Novartis Ag Composes antiviraux de pyridopyrazinedione
KR20250127350A (ko) 2019-09-26 2025-08-26 노파르티스 아게 항바이러스성 피라졸로피리디논 화합물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795740A (en) * 1986-05-20 1989-01-03 Cohen Eric A Antiviral peptides and means for treating herpes infections
GB8815241D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Antiviral combinations & compounds therefor

Also Published As

Publication number Publication date
US5552384A (en) 1996-09-03
EP0493770A3 (en) 1993-03-17
EP0493770B1 (fr) 1997-08-06
AU648855B2 (en) 1994-05-05
IL100549A0 (en) 1992-09-06
ATE156362T1 (de) 1997-08-15
AU9009391A (en) 1992-07-02
EP0493770A2 (fr) 1992-07-08
JP3209552B2 (ja) 2001-09-17
CA2033448C (fr) 1996-11-26
JPH04275229A (ja) 1992-09-30
DE69127184T2 (de) 1997-12-18
DE69127184D1 (de) 1997-09-11
CA2033448A1 (fr) 1992-07-01
NZ241121A (en) 1994-06-27

Similar Documents

Publication Publication Date Title
AU648854B2 (en) Synergistic combination for treating herpes infections
US5484771A (en) Antiherpes peptide derivatives having a 1,4-dioxo-C, N-terminus
CA2033448C (fr) Compositions contre l'herpes et mode d'utilisation
CA1340681C (fr) Tetrapeptides antiherpetiques, a chaine laterale constituee d'acide aspartique avec substitution
US5700780A (en) Antiviral peptide derivatives having a 2-oxoalkyl amino acid side chain
AU683450B2 (en) Inhibitors of herpes viral ribonucleotide reductase
EP0411334B1 (fr) Dérivés pentapeptidiques antiherpès ayant une chaîne latérale d'acide aspartique substitué
US5066783A (en) Antiviral peptides and means for treating herpes infections
CA1340684C (fr) Pentapeptides antiherpetiques
CA1340683C (fr) Pentapeptides antiherpetiques, a chaine laterale constituee d'acide aspartique avec substitution
US5149778A (en) Cyclic peptides for treating herpes infections
EP0560274B1 (fr) Dérivés de peptides anti-herpès ayant une extrémité N-terminale contenant un groupe ureido
IL94982A (en) History of herpes tetrapeptide with a side chain of converted aspartic acid in their preparation and pharmaceutical preparations containing
US5258493A (en) Cyclic peptides for treating herpes infections
US5830864A (en) Antiherpes peptide derivatives having a ureido n-terminus
CA2019005C (fr) Derives pentapeptidiques anti-herpes ayant une chaine laterale d'acide aspartique substitue par un groupement cycloalkyl

Legal Events

Date Code Title Description
FF Patent granted
HP Change in proprietorship
KB Patent renewed
RH Patent void
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees